SEC EDGARSEP 251 min read$OMER

Borges David J. sold $419K of OMER

Borges David J. (VP, Finance & CAO) sold 20,000 shares of OMEROS CORP (OMER) at $20.95 ($0.42M total) across 2 trades over 2026-09-22 to 2026-09-23 under a Rule 10b5-1 trading plan.

Original reporting

SEC EDGAR · Borges David J.

Published Sep 25, 2026, 1:00 AM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Sep 25, 2026, 1:26 AM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

AlphAI market briefInsider activity

Primary signal

$OMER

Bearish

medium confidence

Mentioned

$OMER

Relevance

3/10

AlphAI data visualization · based on SEC EDGAR

Decision brief

The 30-second read

$OMERBearishLow

Why it matters

The complete divestiture by a senior finance officer may prompt short‑term scrutiny but is unlikely to move the broader market.

Market read

Relevant primarily to OMER shareholders; minimal broader market impact.

What to watch

The 10b5‑1 plan pre‑arranged; insider may have had tax or liquidity motives.

Relevance 3/10Novelty 4/10Timing: filed 2026-09-24, effective immediately

Background

Form 4 filings disclose insider transactions; investors monitor them for signals.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$OMERBearishMedium confidence

Context

VP of Finance sold 20,000 shares for $419K via a 10b5‑1 plan, leaving zero holdings.

Expected impact

Potential short‑term dip of 1‑2% as market digests the sale.

Evidence & confidence

Sale size is modest relative to market cap, but complete exit by a senior officer can weigh on sentiment.

Market effects

Sector

None beyond OMER; sector unchanged.

Regional

No regional effect.

Global

Limited to OMER shareholders.

Counterpoint

What could challenge this read

Sale could be purely portfolio rebalancing, not a negative signal.

Key entities

Officer
Borges David J.
VP, Finance & CAO of OMEROS Corp.

Read at source ← All news

SEP 22

$NTRAMedAI 8/10

NTRA Stock Hits All-Time High, OMER Stock Scales 5-Year Peak – What’s Driving Investors’ Enthusiasm Today?

Natera (NTRA) and Omeros (OMER) shares rose on Tuesday, with NTRA hitting an all-time high and OMER reaching a 5-year peak. NTRA's cancer test received Japanese regulatory approval, while OMER was upgraded by Cantor Fitzgerald due to optimism about its lead drug's potential. NTRA is up 5%, OMER up 12% at the time of writing.

stocktwits.com5 min

SEP 19

$OMERMedAI 8/10

OMER Stock Surges 5% After Hours On Novo Nordisk Deal Windfall And Drug Launch Optimism

Omeros Corporation (OMER) shares rose 5% after hours on optimism about its deal with Novo Nordisk and drug launches. Q4 net income was $86.5M, up from a $31.4M loss in 2024, including a $237.6M gain from the zaltenibart transaction. The company expects milestone payments and royalties from Novo Nordisk and anticipates positive cash flow by 2027.

stocktwits.com2 min

AUG 20

$OMERHighAI 8/10

Omeros (OMER) Q2 2026 Earnings Call Transcript

Omeros (OMER) reported Q2 2026 earnings with Yartemlia gross sales at $32.2M, up 190% from Q1. Net income was $13.2M, including a $11.5M non-cash gain. The company reduced debt by 43% and generated $4.1M in operating cash flow. However, the EMA's committee issued a negative opinion on Yartemlia's marketing authorization application for TA-TMA.

fool.com3 min

AUG 18

$OMERMed

Why Omeros (OMER) Is Up 27.5% After Swinging To Profitability And Completing Share Buyback

Omeros (OMER) reported Q2 2026 results moving from net losses to net income of $13.23M, and half-year net income of $69.29M. The company also completed a buyback of 843,187 shares for $9.87M under its Dec 2025 program and expanded its board to nine, adding Joseph Schocken. The article cites an ESOP-related $142.67M shelf registration and forecasts to 2029.

simplywall.st6 min

AUG 14

$OMERMed

Omeros Corporation Q2 2026 Earnings Call Summary

Omeros reported Q2 2026 progress for Yartemlia, citing 188% quarter-over-quarter net sales growth and $4.1 million positive operating cash flow. Management said adult transplant centers now drive about 75% of sales and formulary approval is 55% to 60%. It also discussed cash flow positivity by mid-2027, repurchases, and regulatory items including a July 1 J-code and Oct. 1 NTAP.

yahoo.com5 min

AUG 13

$OMERHighAI 9/10

Why is Omeros stock surging today?

Omeros (OMER) shares rose about 17% in pre-open after the company reported Q2 2026 results. Adjusted EPS was $0.02 versus a consensus $0.25 loss, and revenue was $28.5M versus $12.67M expected. YARTEMLEA sales were $32.2M gross, and Omeros reported GAAP net income of $13.2M and first positive operating cash flow.

investing.com4 min